Page 45 - Haematologica Vol. 109 - July 2024

REVIEW ARTICLE - Minimal residual disease in multiple myeloma R. Szalat et al.
66. Hillengass J, Merz M, Delorme S. Minimal residual disease in multiple myeloma: use of magnetic resonance imaging. Semin Hematol. 2018;55(1):19-21.
67. Messiou C, Giles S, Collins DJ, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol. 2012;85(1020):e1198-1203.
68. Messiou C, Kaiser M. Whole body diffusion weighted MRI-a new view of myeloma. Br J Haematol. 2015;171(1):29-37.
69. Messiou C, Porta N, Sharma B, et al. Prospective evaluation of whole-body MRI versus FDG PET/CT for lesion detection in participants with myeloma. Radiol Imaging Cancer. 2021;3(5):e210048.
70. Belotti A, Ribolla R, Cancelli V, et al. External validation of diffusion weighted whole body MRI (DW-MRI) response assessment category (RAC) criteria proposed by the myeloma response assessment and diagnosis system (MY-RADS) imaging recommendations: prognostic role of imaging response after transplant in multiple myeloma and comparison with MRD evaluation by flow cytometry. Blood. 2020;136(Suppl 1):41-42.
71. Bockle D, Tabares P, Zhou X, et al. Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. Br J Haematol. 2022;198(3)515-522.
72. Oliva S, Genuardi E, Petrucci MT, et al. Impact of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) on outcome: results of newly diagnosed transplant-eligible multiple myeloma (MM) patients enrolled in the Forte trial. Blood. 2020;136(Suppl 1):44-45.
73. Avet Loiseau H, Sonneveld P, Moreau P, et al. Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) negativity in Cassiopeia Part 1 and Part 2. Blood. 2021;138(Suppl 1):82.
74. Medina A, Puig N, Flores-Montero J, et al. Comparison of next- generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10(10):108.
75. Mohan M, Kendrick S, Szabo A, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808-817.
76. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
77. Cortes J, Rea D, Lipton JH. Treatment-free remission with
first- and second-generation tyrosine kinase inhibitors. Am J
Hematol. 2019;94(3):346-357.
78. Paiva B, Manrique I, Rytlewski J, et al. Time-dependent
prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood Cancer Discov. 2023;4(5):365-373.
79. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
80. Corre J, Montes L, Martin E, et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105(9):e480-483.
81. Jakubowiak AJ, Kumar S, Medhekar R, et al. Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma. Oncologist. 2022;27(7):e589-e596.
82. Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901-2912.
83. de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889-2900.
84. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716.
85. Paiva B, San-Miguel JF, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140(23):2423-2428.
86. Abeykoon JP, Murray DL, Murray I, et al. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. 2021;193(2):380-385.
87. Rosinol L, Oriol A, Rios R, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142(18):1518-1528.
88. Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single- centre, phase 2 trial. Lancet Haematol. 2021;8(6):e422-e432.
89. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301-313.
Haematologica | 109 July 2024
2059